Please login to the form below

CRPC

This page shows the latest CRPC news and features for those working in and with pharma, biotech and healthcare.

Trial backs role for Lynparza in second-line prostate cancer

subpopulation of HRRms – namely BRCA1/BRCA2 and ATM mutations – and that makes PROfound “the only positive phase 3 trial of any PARP inhibitor” in CRPC. ... AZ is also conducting a phase 3 trial (PROPEL) of Lynparza in combination with Zytiga as

Latest news

Bayer bags FDA nod for early prostate cancer drug darolutamide

The FDA approved darolutamide under the Nubeqa brand name for men with non-metastatic CRPC, which is shaping up to be a hotly-contested category in prostate cancer. ... It is estimated that around 73, 000 men in the US will be diagnosed with
Bayer gains FDA priority review for prostate cancer drug

Bayer reckons that tolerability is critical in non-metastatic CRPC because patients may be on therapy for years,.
Bayer, Orion prep challenge in prostate cancer market

resistant prostate cancer (CRPC), as they prepare to take on rival therapies from Johnson &Johnson and Pfizer/Astellas. ... Bayer reckons that tolerability is critical in non-metastatic CRPC because patients may be on therapy for years,.
Merck puts prostate cancer firmly in Keytruda’s sights

KEYNOTE-365 data reported at the ASCO Genitourinary Cancers Symposium this week showed that in patients with castration-resistant prostate cancer (CRPC) Keytruda improved the efficacy of Lynparza – a PARP inhibitor ... 1 inhibitor Opdivo (nivolumab)
J&J’s Erleada cleared for early prostate cancer in Europe

Xtandi is also approved for more advanced, metastasised CRPC, where it competes with J&J’s $4bn-plus androgen synthesis inhibitor Zytiga (abiraterone acetate), and reported $180m in alliance revenues in

More from news
Approximately 1 fully matching, plus 37 partially matching documents found.

Latest Intelligence

Drug launches to watch in 2019

In patients with non-metastatic CRPC, there is a high unmet need to delay development of metastases and the progression to advanced prostate cancer. ... for approval in the US and EU for non-metastatic CRPC on the strength of MFS data from the PROSPER

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Senior Medical Writer, Healthcare Advertising Agency: £45, 000 – £50, 000

FREELANCE Medical Writer (Initial 2/ 3 months term) - London Off...: Excellent Daily Rate

Account Director – UK Office: Excellent salary and benefits

Account Director - Healthcare Advertising - London - 2 DAYS HOME...: £50000 - £70000

FREELANCE Account Director – Healthcare Advertising – London – 3...: Competitive Daily Rates

Senior Account Manager > Account Director - London - Medical ...: Salary TBC

Account Director - Medical Communications - London / South East: Excellent Salary and Benefits on offer

Strategic Planner, Healthcare Advertising Agency: Salary TBC

Account Director – London based Medical Communications Agency: Excellent Remuneration Package

Senior Account Executive – Account Manager – Healthcare Advertis...: £32000 - £43000 Bonus Benfits

Account Director, Healthcare Communications: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

OUTiCO

Providing an exceptional outsourcing service to the Pharma & Healthcare industries. We offer a sustainable approach and drive sales outcomes...

Latest intelligence

The relevance of patient perspectives to value: Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?: Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...
The evolution of real-world studies: How industry and regulators are using real-world data...